Linear IgA bullous dermatosis (LABD), also known as linear IgA dermatosis, is a rare immune-mediated disease that results in blistering of the skin, in the subepidermal layers. It is commonly ...

Background: Bullous autoimmune dermatoses are a clinically and immunopathologically heterogeneous group of diseases, characterized clinically by blisters or erosions of the skin and/or mucous ...

Bullous hemorrhagic dermatosis is an uncommon nonimmune adverse drug reaction to heparin-based anticoagulants including unfractionated heparin, low-molecular-weight heparin and fondaparinux that ...

The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...

For centuries, bullous pemphigoid (BP) was grouped with and considered a condition similar to pemphigus vulgaris (PV). In 1953, however, Lever recognized BP as a disorder distinct from PV. 9 BP, the ...

Here, we describe a patient with non-Hodgkin's lymphoma who developed LABD after autologous HSCT and was successfully treated with glucocorticoid, dapsone and high-dose i.v. Ig, but the lymphoma ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

These skin diseases are associated with a range of debilitating symptoms that pose a significant medical burden to patients and often negatively impact their quality of life. 1-4 With these milestones ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 26-month-old boy presented for evaluation of acute ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Linear IgA bullous dermatosis (LABD) is an autoimmune disease that causes blisters. People with LABD can develop blisters in the skin and the mucous membranes in their mouth, genitals, and eyelids.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “Bullous pemphigoid, atopic dermatitis, and chronic spontaneous urticaria continue to represent a significant burden to millions ...